$ACOG

Opaleye Management Inc. purchased $184K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 30,728 indirectly-held shares of Alpha Cognition Inc. (ACOG) at an average of $5.98 ($5.98–$5.99, $0.18M total) across 2 trades over 2026-06-09 to 2026-06-10.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Jun 11, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ACOG
Bullish
medium confidence
Mentioned
$ACOG
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ACOGBullishLow
01

Why it matters

The newest information is the disclosed open-market purchase by a 10% owner, which can modestly influence sentiment but lacks any accompanying fundamental update.

02

Market read

Traders may treat the filing as a small positive sentiment datapoint, but it is unlikely to drive a major repricing without additional catalysts.

03

What to watch

The article provides only the buy details; it does not state intent, remaining plan, or whether other insiders/large holders are acting similarly.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-11; purchases dated 2026-06-09 to 2026-06-10

Background

The article is an SEC Form 4 insider transaction disclosure for Alpha Cognition Inc. (ACOG).

Company-level read

Ticker impact

$ACOGBullishMedium confidence
Context

Opaleye Management Inc. (a 10% owner) bought 30,728 shares of Alpha Cognition (ACOG) for ~$183.7K via open-market purchases (Form 4).

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing discloses a specific buy size and price range, but no accompanying operational/regulatory/financial event is provided.

Market effects

No sector read-across; this is company-specific ownership activity.

None indicated.

None indicated.

Counterpoint

A 10b5-1 plan is explicitly not used, but insider buys can still be routine liquidity/portfolio rebalancing rather than a forward-looking signal.

Key entities

  • Alpha Cognition Inc.

    Company whose shares were purchased; subject of the Form 4 insider transaction.

  • Opaleye Management Inc.

    10% owner reporting the open-market purchase of ACOG shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.